PMID- 20005052
OWN - NLM
STAT- MEDLINE
DCOM- 20100818
LR  - 20220408
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 74
IP  - 5
DP  - 2010 May
TI  - Prophylactic topical heparin can prevent or postpone intravenous cannula induced 
      superficial thrombophlebitis.
PG  - 857-8
LID - 10.1016/j.mehy.2009.11.030 [doi]
AB  - Intravenous cannulation is a cornerstone of today's medical practice. Maintaining 
      a single indwelling intravenous (IV) cannula for long duration is limited by the 
      development of superficial thrombophlebitis (ST). It is a self limiting 
      inflammation and thrombosis of superficial veins. ST presents with fever, pain, 
      erythema, tenderness and cord like swelling. The incidence of ST is high and 
      usually occurs within 72h of IV cannula insertion. The current standard medical 
      therapy for ST is topical heparin application for 7 days. Heparin acts by 
      preventing coagulation rather than lysing a formed clot. So, if topical heparin 
      is started prophylactically even before ST sets in, i.e. from day 1 of IV cannula 
      insertion it can prevent or postpone ST more effectively. It increases the 
      indwelling time of a single IV cannula and can be very useful in high risk groups 
      requiring IV cannulation like patients receiving cancer chemotherapy, ICU 
      patients and infants. It decreases the need for recurrent cannulations and 
      associated morbidity thereby improving patient compliance. It also prevents 
      extended hospital stay due to ST and related complications. High incidence of ST 
      justifies the use of prophylactic topical heparin with all IV cannulations. 
      Prophylaxis will be better than treatment in managing patients with IV cannulas.
FAU - Arun Babu, T
AU  - Arun Babu T
AD  - Department of Pediatrics, Jawaharlal Institute of Post Graduate Medical Education 
      and Research (JIPMER), Puducherry, India. babuarun@yahoo.com
FAU - Sharmila, V
AU  - Sharmila V
LA  - eng
PT  - Journal Article
DEP - 20091211
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Administration, Topical
MH  - Catheterization/*adverse effects
MH  - Heparin/administration & dosage/*pharmacology/*therapeutic use
MH  - Humans
MH  - Infusion Pumps/adverse effects
MH  - Premedication/*methods
MH  - Thrombophlebitis/etiology/*prevention & control
EDAT- 2009/12/17 06:00
MHDA- 2010/08/19 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/11/19 00:00 [received]
PHST- 2009/11/22 00:00 [accepted]
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/08/19 06:00 [medline]
AID - S0306-9877(09)00787-7 [pii]
AID - 10.1016/j.mehy.2009.11.030 [doi]
PST - ppublish
SO  - Med Hypotheses. 2010 May;74(5):857-8. doi: 10.1016/j.mehy.2009.11.030. Epub 2009 
      Dec 11.